Table 2.
Patient characteristics and the association with ACVR1B gene status
|
Patients characteristics |
ACVR1B
gene |
P
|
|
|---|---|---|---|
| Not deletion (n = 23) | Deletion (n = 6) | ||
| Age |
|
|
|
| <70 years |
15 |
3 |
0.65 |
| ≥ 70 years |
8 |
3 |
|
| Gender |
|
|
|
| Male |
12 |
3 |
1.00 |
| Female |
11 |
3 |
|
| Primary size |
|
|
|
| <2 cm |
18 |
5 |
1.00 |
| ≥2 cm |
5 |
1 |
|
| Lymph node metastasis |
|
|
|
| Negative |
4 |
0 |
0.55 |
| Positive |
19 |
6 |
|
| Distant metastasis |
|
|
|
| Negative |
10 |
4 |
0.39 |
| Positive |
13 |
2 |
|
|
SMAD4 gene status |
|
|
|
| Not deletion |
18 |
1 |
0.011* |
| Deletion |
5 |
5 |
|
| Treatment |
|
|
|
| Best supportive care |
4 |
2 |
0.59 |
| Chemotherapy |
17 |
4 |
|
| Unknown |
2 |
0 |
|
| Response to chemotherapy |
|
|
|
| PR |
7 |
1 |
1.00 |
| SD or PD |
10 |
3 |
|
| Median PFS (days) |
252 |
167 |
0.89 |
| Median OS (days) | 344 | 215 | 0.66 |
ACVR1B, activin receptor A, type IB; PR, partial response; SD, stable disease; PD, progressive disease; PFS, progression-free survival; OS, overall survival. PFS and OS were analyzed by log-rank test and the others by Fisher exact test.
Legend: Six patients (6/29, 20.7%) had a deletion of ACVR1B gene, 10 patients (10/29, 34.5%) had a deletion of SMAD4 gene. Five of the 6 patients with a deletion of the ACVR1B gene also had a deletion of the SMAD4 gene (P = 0.011), but no significant differences in the other patient characteristics were observed between the two groups. Among 21 patients who received chemotherapy, no significant differences in PFS or OS were seen between the two groups.